The present invention relates to an improved process for the preparation of Solifenacin or its salt of formula I more particularly the present invention relates to an economically viable and industrially advantageous process for the preparation of highly pure Solifenacin or its salt of formula I. ...

The present invention relates to a novel process for the preparation of tetralin and naphthalene derivatives of formula (IV) including Agomelatine and pharmaceutical acceptable salts thereof. Such compounds are considered to be interesting either as useful building blocks or due to their biological activity. The com...

The present invention relates to a novel preparation method for 2 (3 cyano 4 isobutoxyphenyl) 4 methyl 1 3 thiazole 5 carboxylic acid (Febuxostat) via novel and high yielded conversion of a formyl group in to a cyano group.

The present invention relates to an improved process for the preparation of Duloxetine and pharmaceutical acceptable salts or derivatives thereof in particular to a process for large scale production of Duloxetine hydrochloride in high yield and high enantiomeric and chemical purity.

The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Diba...

The present invention relates to novel preparation methods for Topiroxostat through novel intermediates comprising novel methods for the formation of the triazole ring and for the cyanation of the pyridyl ring.

The present invention relates to an improved process for the synthesis of Paliperidone compound of formula I in high purity. The present invention relates to an economically viable and industrially feasible process for the preparation of Paliperidone and intermediates thereof.

SEE ATTACHED

SEE ATTACHED

The present invention relates to a novel preparation method for (S)-1-(3,4-dimethoxy bicyclo [4.2.0] octa - 1, 3, 5 - trien - 7 - yl) - N - methylmethanamine, key intermediate for the preparation of Ivabradine or any pharmaceutical acceptable salt, hydrate or solvate thereof via selective reduction of cyano group an...

The present invention relates to an improved process for the preparation of Montelukast and pharmaceutical acceptable salts or derivatives thereof in particular to a process for large scale production of Montelukast and salts thereof in high yield and high purity and pharmaceutical preparations containing said compo...

SEE ATTACHED

HHThe present invention provides an improved industrially feasible process for the preparation of 2 amino 9 ((2 phenyl 1 3 dioxan 5 yloxy)methyl) 1 purin 6(9) one Formula which is a useful intermediate for the preparation of Valganciclovir and pharmaceutically acceptable salts thereof and involves the use of said ne...

The present invention relates to an improved process for the preparation of essentially pure Venlafaxine Hydrochloride. Particularly, the process for the preparation of Venlafaxine Hydrochloride comprises the following steps: i) Preparation of 1-[Cyano-1-(4-methoxyphenyl) methyl] cyclohexanol, ii) Preparation of cru...

The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a proc...

The present invention relates to a novel process for the preparation of tryptamine its substituted derivatives and intermediates for the preparation of them.

The present invention relates to an improved process for the preparation of high pure crystalline Aripiprazole of formula (I) having low residue ethanol content. The process comprises slurrying Aripiprazole obtained from the reaction mixture with water.

The invention discloses a novel and selective methylation process used in the preparation of Raltegravir and intermediates. Further disclosed is an improved method for the reaction of intermediate amine compound of formula IIb with oxadiazole intermediate compound of formula V.

A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.

The present invention relates to a stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising Levothyroxine. It also relates to a process for the preparation of microparticles and use to control hypothyroidism in adults, congenital hypothyroidism in infants and ...

The present invention relates to a long acting injectable formulation based on combination of biodegradable poly(D,L-lactide-co-glycolide) microparticles comprising different PLGA polymers and Tacrolimus. It also relates to a process for the preparation of microparticles & use thereof.